Genmab A/S schedules annual general meeting
COPENHAGEN, Denmark - Genmab A/S (NASDAQ:GMAB), a biotechnology company specializing in pharmaceutical preparations with a market capitalization of $12.2 billion and an impressive 95% gross profit ...
Genmab upgraded to Outperform from Market Perform at Leerink
Leerink analyst Jonathan Chang upgraded Genmab (GMAB) to Outperform from Market Perform with a $27 price target, citing a longer-term view ...
Taiwan News3d
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2024 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by ...
Insider Monkey7d
Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts
In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry witnessed ...